v3.26.1
Segment Reporting (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Abstract]            
Number of operating segments | segment         1  
Number of reportable segments | segment         1  
Segment Reporting [Line Items]            
Total revenue $ 1,488   $ 1,373   $ 3,022 $ 2,854
Total research and development 10,690   8,402   21,945 17,932
General and administrative 7,242   6,766   15,359 13,218
Total operating expenses 17,932   15,168   37,304 31,150
Loss from operations (16,444)   (13,795)   (34,282) (28,296)
Other income (expense):            
Interest income 395   227   526 571
Interest expense (4,476)   (1,285)   (5,796) (2,543)
Loss on extinguishment of debt (2,383)   0   (2,383) 0
Change in fair value of derivative liability (1,891)   0   (1,891) 0
Other (expense) income, net (78)   114   (228) 179
Total other (expense) income (8,433)   (944)   (9,772) (1,793)
Net loss (24,877) $ (19,177) (14,739) $ (15,350) (44,054) (30,089)
Collaborative Arrangements            
Segment Reporting [Line Items]            
Total revenue 1,488   1,373   3,022 2,854
Total research and development 400   300   1,300 1,100
Reportable Segment            
Segment Reporting [Line Items]            
Research and development personnel costs 5,150   4,091   10,752 8,106
Facilities and other support costs 842   834   1,675 1,815
Other 594   72   1,465 1,149
Total research and development 10,690   8,402   21,945 17,932
General and administrative 7,242   6,766   15,359 13,218
Total operating expenses 17,932   15,168   37,304 31,150
Loss from operations (16,444)   (13,795)   (34,282) (28,296)
Other income (expense):            
Interest income 395   227   526 571
Interest expense (4,476)   (1,285)   (5,796) (2,543)
Loss on extinguishment of debt (2,383)   0   (2,383) 0
Change in fair value of derivative liability (1,891)   0   (1,891) 0
Other (expense) income, net (78)   114   (228) 179
Total other (expense) income (8,433)   (944)   (9,772) (1,793)
Net loss (24,877)   (14,739)   (44,054) (30,089)
Reportable Segment | OCU400            
Segment Reporting [Line Items]            
Research and development expense (excluding acquired in process cost) 2,211   1,998   3,520 3,843
Reportable Segment | OCU410 and OCU410ST            
Segment Reporting [Line Items]            
Research and development expense (excluding acquired in process cost) 1,590   1,117   3,966 2,295
Reportable Segment | NeoCart            
Segment Reporting [Line Items]            
Research and development expense (excluding acquired in process cost) 196   8   218 5
Reportable Segment | COVAXIN            
Segment Reporting [Line Items]            
Research and development expense (excluding acquired in process cost) 3   0   10 0
Reportable Segment | Inhaled mucosal vaccine platform            
Segment Reporting [Line Items]            
Research and development expense (excluding acquired in process cost) 49   131   79 319
Reportable Segment | OCU200            
Segment Reporting [Line Items]            
Research and development expense (excluding acquired in process cost) 55   151   260 400
Reportable Segment | Collaborative Arrangements            
Segment Reporting [Line Items]            
Total revenue $ 1,488   $ 1,373   $ 3,022 $ 2,854